Development of Melioidosis Subunit Vaccines Using an Enzymatically Inactive *Burkholderia pseudomallei* AhpC

Lindsey K. Schmidt,*a Caitlyn E. Orne,a Teresa L. Shaffer,a§ Shane M. Wilson,b Nittaya Khakhum,b Alfredo G. Torres,b Paul J. Brett,a,c Mary N. Burtnicka,c

aDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA
bDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA
cDepartment of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

**ABSTRACT**  *Burkholderia pseudomallei*, the causative agent of melioidosis, is a facultative intracellular, Gram-negative pathogen that is highly infectious via the respiratory route and can cause severe, debilitating, and often fatal diseases in humans and animals. At present, no licensed vaccines for immunization against this CDC Tier 1 select agent exist. Studies in our lab have previously demonstrated that subunit vaccine formulations consisting of a *B. pseudomallei* capsular polysaccharide (CPS)-based glycoconjugate (CPS-CRM197) combined with hemolysin-coregulated protein (Hcp1) provided C57BL/6 mice with high-level protection against an acute inhalational challenge of *B. pseudomallei*. In this study, we evaluated the immunogenicity and protective capacity of *B. pseudomallei* alkyl hydroperoxide reductase subunit C (AhpC) in combination with CPS-CRM197. AhpC is a peroxiredoxin involved in oxidative stress reduction and is a potential protective antigen. To facilitate our studies and maximize safety in animals, recombinant *B. pseudomallei* AhpC harboring an active site mutation (AhpCC57G) was expressed in *Escherichia coli* and purified using tandem nickel-cobalt affinity chromatography. Immunization of C57BL/6 mice with CPS-CRM197 combined with AhpCC57G stimulated high-titer IgG responses against the CPS component of the glycoconjugate as well as stimulated high-titer IgG and robust interferon gamma (IFN-γ), interleukin-5 (IL-5), and IL-17-secreting T cell responses against AhpCC57G. When challenged via an inhalational route with a high dose (~27 50% lethal doses [LD₅₀]) of *B. pseudomallei*, 70% of the immunized mice survived 35 days postchallenge. Collectively, our findings demonstrate that AhpCC57G is a potent activator of cellular and humoral immune responses and may be a promising candidate to include in future melioidosis subunit vaccines.

**KEYWORDS** *Burkholderia pseudomallei*, melioidosis, capsular polysaccharide, glycoconjugate, alkyl hydroperoxide reductase, subunit vaccine
rates for leptospirosis and dengue fever (5). With the potential to impact over 79 countries, the global threat of melioidosis cannot be understated, and the prevention, diagnosis, and treatment of melioidosis are of paramount importance. In addition to its impact on public health, *B. pseudomallei* has the potential for misuse as a bioterrorism agent and is currently categorized as a Tier 1 select agent by the U.S. Centers for Disease Control and Prevention (CDC) (6).

*B. pseudomallei* is a motile, aerobic, facultative intracellular pathogen and a soil- and water-dwelling bacterium (7, 8). Acquisition of *B. pseudomallei* typically occurs through inhalation of aerosolized soil or water, percutaneous inoculation, or ingestion of contaminated food or water (4). The organism is naturally resistant to a variety of antibiotics, and there is high mortality associated with acute forms of the disease. Mortality rates can be as high as 50% in some regions of endemicity, which can increase to 80% if patients have one or more predisposing conditions, such as diabetes, alcoholism, chronic lung disease, chronic renal disease, thalassemia, or cancer, or are undergoing immunosuppressive therapy (9).

*B. pseudomallei* infections can be difficult to treat and require intravenous ceftazidime or meropenem for at least 10 to 14 days, followed by 3 to 6 months of oral trimethoprim-sulfamethoxazole (10). Currently, there are no licensed vaccines available for immunization against melioidosis (6).

*B. pseudomallei* is a versatile pathogen that is capable of both extracellular and intracellular growth (11). Following infection, the organism can invade host cells, escape from phagosomes, survive within the cytosol, and spread from cell to cell in almost any tissue of the body (12–14). The *B. pseudomallei* genome is large (~7.2 Mb) and is estimated to carry approximately 5,855 coding sequences involved in a myriad of functions that enable survival in a range of environments (15, 16). The organism is resistant to host complement-mediated killing and has an abundance of virulence genes that are expressed following infection (15, 16). While surface polysaccharides such as the 6-deoxyheptan capsular polysaccharide (CPS) and the O-polysaccharide (OPS) component of lipopolysaccharide contribute to complement and serum resistance, *B. pseudomallei* also expresses a number of specialized secretion systems and detoxifying enzymes that facilitate its intracellular lifestyle (7). Due to the complex life cycle of *B. pseudomallei* and its tendency to cause persistent infections, an effective vaccine will need to stimulate both protective humoral and cellular immune responses.

Previous preclinical vaccine studies have explored the use of live attenuated bacteria, outer membrane vesicles, nanoparticle platforms, glycoconjugates, and multivalent subunit formulations with varied success (10, 17–26). Research in our lab focuses on the development of glycoconjugate-based subunit vaccines, an approach that is generally considered safe and utilizes a defined set of antigens, which allows for the determination of antigen-specific correlates of immunity (1, 6, 19, 24, 27). Previously, we demonstrated that mice immunized with CPS-based glycoconjugates along with recombinant *Burkholderia* proteins (e.g., LolC and TssM) were provided with significant protection against lethal challenges of *B. pseudomallei* (19, 24). Most recently, we found that when C57BL/6 mice were immunized with CPS conjugated to the diphtheria toxin mutant CRM197 (CPS-CRM197), combined with hemolysin-coregulated protein 1 (Hcp1) and adjuvanted with Alhydrogel and CpG, 100% of the mice were protected against a lethal inhalational challenge of *B. pseudomallei*, and 70% of the survivors had no culturable bacteria in their lungs, livers, or spleens (19). The immunized mice exhibited high-titer CPS-specific IgG responses that were opsonizing as well as high-titer Hcp1-specific IgG levels and robust interferon gamma (IFN-γ)-secreting T cell responses (19). Extending these findings, we have begun to explore the use of CPS-CRM197 in combination with different proteins that show promise as protective antigens to improve our existing vaccine formulation.

In the present study, we investigated the immunogenicity and protective capacity of *B. pseudomallei* alkyl hydroperoxide reductase subunit C (AhpC) when combined with CPS-CRM197. AhpC homologs are highly conserved across *Burkholderia* spp., and *B. pseudomallei* ahpC (BPSL2096) has been shown to be virtually invariant among
clinical isolates (28). AhpC is a peroxiredoxin involved in protection against oxidative stress and is an immunodominant antigen that induces strong T cell-mediated responses in melioidosis patients (28-31). AhpC has been used as a serodiagnostic target and is considered a protective antigen and promising vaccine candidate (28, 29, 32). To facilitate our studies and maximize safety in animals, we purified a recombinant version of B. pseudomallei AhpC harboring an active site mutation (AhpC\textsuperscript{C57G}). Results showed that a subunit vaccine consisting of CPS-CRM197 plus AhpC\textsuperscript{C57G} formulated with Alhydrogel and CpG provided high-level protection against a lethal aerosol challenge of B. pseudomallei in C57BL/6 mice.

RESULTS

Production of recombinant B. pseudomallei AhpC and AhpC\textsuperscript{C57G}. AhpC enzymes are found in most prokaryotes and belong to a family of 2-Cys peroxiredoxins that catalyze the reduction of hydroperoxides for protection against oxygen radical damage (33). Previous studies have shown that there are two or three conserved cysteine residues critical for the enzymatic activity of AhpC: one at the N terminus (the peroxidatic cysteine, C\textsubscript{P}) and one or two at the C terminus (the resolving cysteine, C\textsubscript{R}) (34, 35). Zhang et al. recently characterized Burkholderia thailandensis AhpC and identified a C\textsubscript{P} at position 57 and two C\textsubscript{R} residues at positions 171 and 173 (31). As shown in Fig. 1a, the primary amino acid sequence of B. pseudomallei AhpC is 100% identical to that of B. thailandensis AhpC and harbors the same three cysteine residues (Cys57, Cys171, and Cys173). To mutate the active site of B. pseudomallei AhpC, the conserved N-terminal C\textsubscript{P} (Cys57) was substituted with a glycine since it lacks a sulfur group and thus prevents the formation of the disulfide bonds that are necessary for AhpC activity (34). The resulting protein was designated AhpC\textsuperscript{C57G} (see Table 1). N-terminal His-tagged versions of recombinant AhpC and AhpC\textsuperscript{C57G} were expressed and purified from Escherichia coli using tandem nickel-cobalt chromatography, essentially as previously described for Hcp1 (36-38). The purity and structural integrity of AhpC and AhpC\textsuperscript{C57G} were assessed by SDS-PAGE (Fig. 1b). The endotoxin concentrations of the purified proteins were determined to be <21 endotoxin units (EU)/mg using a Limulus amoebocyte lysate (LAL) assay.

To test the enzymatic activity of AhpC versus AhpC\textsuperscript{C57G}, H\textsubscript{2}O\textsubscript{2} reduction was measured using a peroxidase activity assay. Following incubation of the proteins with H\textsubscript{2}O\textsubscript{2}, residual H\textsubscript{2}O\textsubscript{2} levels were measured using an iron and xylenol orange reagent that produces a measurable color change. As shown in Fig. 1c, AhpC reduced significantly more H\textsubscript{2}O\textsubscript{2} than AhpC\textsuperscript{C57G}. The level of AhpC\textsuperscript{C57G} activity was similar to that of Hcp1, which was used as a negative control. Horseradish peroxidase (HRP) was used as a positive control in the assay, and as expected, resulted in the largest amount of H\textsubscript{2}O\textsubscript{2} being reduced. These results indicated that the N-terminal Cys57 residue is required for AhpC activity and acts as a C\textsubscript{P} in the active site of the enzyme. Based on these findings, the enzymatically inactive protein AhpC\textsuperscript{C57G} was used in subsequent experiments.

Identification of T cell-restricted epitopes in AhpC\textsuperscript{C57G} and T cell subtype reactivity against AhpC\textsuperscript{C57G}. Previous studies have shown that T cell responses to B. pseudomallei AhpC correlate with survival in melioidosis patients (28, 29). These responses were predominantly associated with CD4\textsuperscript{+} T cells, and two human-specific immunodominant peptides were identified using IFN-\gamma enzyme-linked immunosorbent spot (ELISpot) assays (29). To facilitate the analysis of T cell responses to AhpC\textsuperscript{C57G} in C57BL/6 mice, we conducted epitope mapping experiments using a peptide library consisting of 15-mers that overlapped by 10 amino acids (aa) (see Table 2 below). To generate immune splenocytes for use in these studies, mice were immunized three times with AhpC\textsuperscript{C57G} formulated with Alhydrogel and CpG. One week after the final boost, IFN-\gamma (Th1-like cytokine), IL-5 (Th2-like cytokine), and IL-17 (Th17-like cytokine) ELISpot assays were conducted using the individual peptides as recall antigens. Of the 35 peptides tested, peptides 1 and 2 stimulated robust IFN-\gamma, IL-5, and IL-17-secreting T cell responses, indicating a T cell-restricted epitope is located at the N terminus of AhpC\textsuperscript{C57G} (Fig. 2a to c). Additionally, peptides 9 to 11 stimulated both IFN-\gamma and IL-17-secreting T cell responses, indicating that a second T cell
AhpC as a Novel Melioidosis Vaccine Candidate

Infection and Immunity

August 2022 Volume 90 Issue 8 10.1128/iai.00222-22

epitope is present starting ~41 aa downstream from the N terminus. Interestingly, peptide 12 was found to stimulate only IFN-γ-secreting T cell responses, indicating the presence of a third unique T cell epitope in AhpCC57G.

To determine the T cell population(s) that recognized AhpC-specific peptides 2 and 12, splenocytes from mice immunized with AhpCC57G were pooled, depleted of either CD4+ or CD8+ T cells, and then analyzed using IFN-γ ELISpot assays (Fig. 2d). Flow cytometry was used to confirm efficient depletion of CD4+ or CD8+ T cells in each of the samples (data not shown). The results showed that depletion of CD4+ T cells led to a significant reduction (P < 0.05) in the number of IFN-γ-secreting T cells that responded to AhpCC57G and peptide 2. Conversely, depletion of CD8+ T cells resulted in significantly reduced numbers (P < 0.05) of IFN-γ-secreting T cells that responded to peptide 12. Taken together, these findings suggest that AhpCC57G harbors epitopes that are recognized by both CD4+ and CD8+ T cells in CS7BL/6 mice.

Analysis of antibody responses raised against CPS-CRM197 and AhpCC57G, CPS-based glycoconjugates in combination with recombinant Burkholderia proteins have previously been shown to stimulate robust antibody responses in mice (19, 24). To
assess the immunogenicity of our vaccine formulation, groups of C57BL/6 mice were immunized with either adjuvant only or CPS-CRM197 plus AhpCC57G. One week after the final boost, serum was collected, and antigen-specific IgM and IgG titers were determined by enzyme-linked immunosorbent assay (ELISA). Results of these analyses showed that the vaccine antigens stimulated the production of high-titer IgM (mean endpoint titers of $10^4$) and total IgG (mean endpoint titers of $10^5$) responses against CPS (Fig. 3a). As expected, the combination of antigens also stimulated the production of IgM (mean endpoint titers of $10^2$) and high-titer total IgG (mean endpoint titers of $10^5$) responses against AhpCC57G (Fig. 3b). Analysis of IgG1 and IgG2b levels in the immune serum samples revealed that relatively balanced Th2/Th1-type responses were generated against both antigens (Fig. 3a and b). Additionally, Western immunoblotting was conducted using whole-cell lysates of B. pseudomallei Bp82 and B. thailandensis E555 and demonstrated that the CPS- and AhpCC57G-specific antibodies also reacted with native B. pseudomallei and B. thailandensis antigens (Fig. 3c).

To assess the functionality of the CPS-CRM197 and protein-specific antibodies, opsonophagocytosis assays were conducted. Since B. thailandensis E555 is avirulent, possesses the same 6-deoxyheptan CPS and AhpC as B. pseudomallei, and behaves similarly in RAW 264.7 mouse macrophages, this strain was used in opsonophagocytosis assays to eliminate the need for these studies to be conducted using biosafety level 3 (BSL3) containment (39). As shown in Fig. 4, preincubation of B. thailandensis E555 with heat-inactivated (HI) pooled antiserum from mice immunized with CPS-CRM197 plus AhpC$^{57G}$ significantly enhanced bacterial uptake (>5-fold) into RAW 264.7 cells compared to serum from nonconjugate controls. As expected, serum obtained from mice immunized with adjuvant only and AhpCC57G exhibited no differences in uptake in comparison to the medium-only controls. Collectively, these results demonstrate that the conjugate material used in our vaccine formulation was capable of stimulating opsonizing antibody responses in C57BL/6 mice.

### Analysis of Cellular Immune Responses Raised Against CPS-CRM197 and AhpC$^{57G}$

Tapia et al. have previously demonstrated that immunity provided by multicomponent gold nanoparticle vaccines is associated with mixed Th1 and Th17 responses in a mouse model of melioidosis (25). It is also well established that IFN-γ-secreting T cell responses against various *Burkholderia* proteins correlate with survival of melioidosis patients (29, 40). Of note, AhpC has been shown to elicit some of the strongest T cell responses in survivors compared to other immunoreactive B. pseudomallei proteins (28, 29). To assess the AhpC-specific T cell responses following immunization of C57BL/6 mice with CPS-CRM197 plus AhpC$^{57G}$, single-cell splenocyte suspensions were prepared, restimulated with AhpC$^{57G}$, peptide 2,
and peptide 12, and then analyzed using IFN-γ, IL-5, and IL-17 ELISpot assays to assess Th1-, Th2-, and Th17-like cellular immune responses, respectively. As shown in Fig. 5a, all mice exhibited robust IFN-γ-secreting T cell responses to all stimuli in comparison to the adjuvant-only control. In addition, AhpCC57G and peptide 2, but not peptide 12, stimulated robust IL-5- and IL-17-secreting T cell responses in comparison to the adjuvant-only controls (Fig. 5b and c). These findings are consistent with the results of our peptide mapping experiments and demonstrate that the vaccine formulation CPS-CRM197 plus AhpCC57G stimulates robust IFN-γ-, IL-5-, and IL-17-secreting T cell responses in C57BL/6 mice.

Evaluation of the protective capacity of CPS-CRM197 plus AhpCC57G in a mouse challenge study. To determine the protective capacity of CPS-CRM197 plus AhpCC57G in an animal model of melioidosis, immunized C57BL/6 mice were challenged with high inhalational doses (27 or 28 50% lethal doses [LD50s]) of *B. pseudomallei* K96243 5 weeks after the final boost and then monitored for signs of morbidity and mortality over a 35-day period. As expected, all the mice in the adjuvant-only group (challenged with 20 or 29 LD50s) rapidly succumbed to infection (<5 days). In contrast, 70% of the mice immunized with AhpCC57G plus CPS-CRM197 survived for the duration of the experiment (Fig. 6). This experiment demonstrates the vaccinogenic potential of AhpCC57G in combination with CPS-CRM197 and suggests that inclusion of AhpCC57G in future formulations warrants further investigation.

**DISCUSSION**

The development of subunit vaccines represents a promising approach for immunization against melioidosis. These types of vaccines are antigenically defined and can
be rationally designed to include protective antigens that have been identified through studies using human melioidosis samples and/or in animal models of melioidosis (28, 29, 36, 40–43). Based on current evidence, a vaccine that stimulates both humoral and cellular immune responses will be necessary for robust protection against melioidosis. Several studies have shown that the 6-deoxyheptan CPS expressed by *B. pseudomallei* is a key protective antigen that, when administered to mice as a glycoconjugate, stimulates high-titer IgG responses that are opsonizing (1, 19, 24). A number of protein antigens that correlate with protective T cell immunity in melioidosis patients have also been identified (28, 29, 40, 43). In previous studies, we have combined proteins such as Hcp1, TssM, and LolC with CPS-based glycoconjugates and assessed their potential as melioidosis vaccine candidates (19, 24). In this study, we admixed a CPS-CRM197 glycoconjugate with AhpCC57G in the presence of Alhydrogel and CpG and demonstrated that this combination of antigens stimulated robust CPS- and AhpCC57G-specific antibody responses along with AhpCC57G-specific T cell responses in C57BL/6 mice. In addition, 70% of mice immunized with this formulation survived for 35 days following a high-dose aerosol challenge with *B. pseudomallei*.

The peroxiredoxin AhpC is an abundant, immunogenic protein that is considered a potential vaccine candidate for a variety of bacterial species, including *Campylobacter jejuni*, *Helicobacter pylori*, *Bacillus anthracis*, *Mycobacterium tuberculosis*, *Streptococcus zooepidemicus*, and *Salmonella enterica* serovar Typhimurium (44–48). *B. pseudomallei* AhpC has homology to the AhpC proteins from several of these organisms and harbors three conserved cysteine residues that are required for its function (31). AhpC is conserved across *Burkholderia* species, and in *B. thailandensis*, it has been demonstrated...
that AhpC plays a critical role in defense against oxidative stress (31). *B. pseudomallei* AhpC was identified as a serodominant antigen in a protein microarray study that assessed the reactivity with 747 individual serum samples from melioidosis patients and healthy donors from Singapore and Thailand. While AhpC was reactive with serum from melioidosis patients, it had low reactivity with serum from healthy donors (42). *B. pseudomallei* AhpC has also been shown to induce strong T cell-mediated responses in patients with acute melioidosis and was correlated with their survival (28, 29). Herein, we overexpressed *B. pseudomallei* AhpC in *E. coli* in soluble form and purified it in high yield to homogeneity using tandem nickel-cobalt chromatography. We also produced AhpC57G, an enzymatically inactive version of the protein that would be considered safer for use as a vaccine candidate. His-tagged AhpC57G was isolated using the same procedure developed for His-tagged AhpC and resulted in high yields of pure protein.

Consistent with previous studies, our results demonstrated that *B. pseudomallei* AhpC is a highly immunogenic protein since immunization of mice with AhpC57G alone or in combination with CPS-CRM197 resulted in the production of robust antibody and/or mixed Th1-, Th2-, and Th17-like T cell responses (28, 29). Importantly, the antibodies raised against the recombinant AhpC57G recognized native AhpC in whole-cell lysates of *B. thailandensis* E555, which allowed for the assessment of the opsonizing capacity of both AhpC57G- and CPS-specific antibodies in opsonophagocytosis.
assays. While CPS antibodies promoted uptake of *B. thailandensis* into RAW 264.7 cells, AhpC<sup>57G</sup> antibodies did not. These results confirmed the functionality of the CPS-specific antibodies generated against the formulation containing CPS-CRM197 combined with AhpC<sup>57G</sup>. Peptide mapping studies also revealed the potential presence of both CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses against the conjugate plus AhpC<sup>57G</sup> formulation.

**FIG 4** Functional analysis of antibody responses raised against CPS-CRM197 and AhpC<sup>57G</sup>. C57BL/6 mice (*n* = 4 to 6 per group) were immunized on days 0, 21, and 35 with adjuvant only, AhpC<sup>57G</sup>, or CPS-CRM197 plus AhpC<sup>57G</sup>. Immune serum samples were collected on day 42. *B. thailandensis* E555 was incubated with medium only (no-serum control), pooled HI adjuvant-only immune serum, pooled HI AhpC<sup>57G</sup>-only immune serum, and pooled HI conjugate-plus-AhpC<sup>57G</sup> immune serum. Following incubation for 1 h, opsonized bacteria were added to RAW 264.7 murine macrophage monolayers. Uptake was quantitated at 3 h postinfection. Bars represent the means ± SD of results from three individual assays conducted in triplicate. Values are representative of three independent experiments conducted on different days. *, *P* < 0.05.

**FIG 5** Characterization of cellular immune responses raised against AhpC<sup>57G</sup>. C57BL/6 mice (*n* = 4 per group) were immunized on days 0, 21, and 35 with CPS-CRM197 plus AhpC<sup>57G</sup>. Spleens were harvested on day 42, and (a) IFN-γ, (b) IL-5, and (c) IL-17-secreting T cell responses against AhpC<sup>57G</sup>, peptide 2, and peptide 12 were quantitated by ELISpot. White and black dots represent the means of assays conducted in duplicate for individual mice. Black bars represent geometric means for each group. *, *P* < 0.05.
Identification of peptides 2 and 12 was particularly useful for assessment of AhpCC57G-specific IFN-γ T cell responses via ELISpot assay. When stimulated with whole AhpCC57G protein, the number of spot-forming cells (SFCs) in the adjuvant-only control mice was higher than anticipated. The reason for this phenomenon is unclear, but it is not inconsistent with ELISpot data obtained from T cell studies using human seronegative controls (29). Use of these peptides in the IFN-γ ELISpot assays resulted in reduced background levels in the adjuvant-only controls and thus will be useful for future studies focused on AhpCC57G as a potential vaccine candidate.

Additionally, peptides 2, 9, and 12 may be useful for helping to define correlates of immunity associated with this protein due to the three distinct cytokine patterns that they appear to stimulate (e.g., peptide 2 stimulates IFN-γ, IL-5, and IL-17, peptide 9 stimulates IFN-γ and IL-17, and peptide 12 stimulates IFN-γ).

In a high-dose (27 to 28 LD₅₀s) aerosol challenge study, 70% of the mice immunized with AhpCC57G and CPS-CRM197 survived for 35 days following exposure to B. pseudomallei. While this is a promising result, this level of protection is below what has previously been observed using CPS-CRM197 in combination with Hcp1 (100%) or TssM (80%) (19). It should be noted, however, that those experiments were conducted with a significantly lower challenge dose (~10 LD₅₀s) (19). Collectively, our results show that AhpCC57G is a potent activator of cellular and humoral immune responses, and based on the outcome of the challenge studies, this warrants further investigation as a potential melioidosis vaccine candidate. Future studies examining the protective capacity of AhpCC57G alone or in combination with existing CPS-CRM197-based vaccine formulations are underway.

MATERIALS AND METHODS

Bacterial strains, plasmids, and growth conditions. The bacterial strains and plasmids used in this study are described in Table 1. E. coli strains with plasmids were cultured on Luria-Bertani-Lennox (LB; Fisherbrand) agar or in LB broth containing ampicillin (100 μg/mL). B. pseudomallei Bp82 was cultured in LB broth or on LB agar supplemented with thiamine (5 μg/mL) and adenine (100 μg/mL). B. thailandensis BT2683, B. thailandensis E264, and B. pseudomallei K96243 were cultured in LB broth or on LB agar. For Western immunoblotting experiments, B. pseudomallei Bp82 and B. thailandensis E264 were cultured in Difco M9 minimal salts supplemented with 0.4% glucose and 0.5% (wt/vol) Bacto Casamino Acids (M9CG; BD) with or without thiamine and adenine, respectively. All bacterial cultures were incubated at 37°C; broth cultures were incubated with shaking (200 rpm). Bacterial stocks were maintained at −80°C in 20% glycerol suspensions. All manipulations of B. pseudomallei K96243 were conducted in CDC/USDA-approved and registered BSL3 or animal biosafety level 3 (ABS3L3) facilities at the University of Texas Medical Branch, and experiments were performed in compliance with the rules and regulations of the U.S. Federal Select Agent Program.

Sequence alignment. Protein sequences were aligned using CLUSTAL 2.1. The RefSeq accession numbers for sequences are as follows: WP_004192241.1 (Burkholderia pseudomallei K96243), WP_004192241.1 (Burkholderia mallei ATCC 23344), WP_004192241.1 (Burkholderia thailandensis E264), WP_034207560.1
**Glycoconjugate synthesis.** CPS was purified from *B. thailandensis* BT2683 using a modified hot aqueous-pHENOL procedure essentially as previously described (1, 27). Recombinant, preclinical-grade CRM197 was purchased from Fina Biosolutions. The CPS-CRM197 glycoconjugates used in this study were synthesized as previously described (27). A bicinchoninic acid (BCA) assay kit (Pierce) was used to quantitate the protein concentration of the glycoconjugate stock. (The remainder of the mass was assumed to be polysaccharide.) The glycoconjugate material used in this study contained 60% (wt/wt) CPS.

**Protein expression and purification.** For expression of recombinant AhpC with an N-terminal 6×His tag, the ahpC open reading frame (ORF) (BPSL2096) was PCR amplified from *B. pseudomallei* K96243 genomic DNA using the BpAhpC-6HisF (5′-CCCCACGGTTCCCATGCGGCGCATCATCATTACATAACAGCCGCGGAAACTGG-3′) and BpAhpC-R1 (5′-CCCCACGGTTCCCATGCGGCGCATCATCATTACATAACAGCCGCGGAAACTGG-3′) primer pair; BsmBI recognition sites are underlined. The resulting DNA fragment was digested with BsmBI and cloned into pBAD/HisA digested with NcoI/HindIII, producing plasmid pBAD/AhpC. The glycoconjugate material used in this study contained 60% (wt/wt) CPS. For expression of recombinant AhpC<sup>CC57G</sup> with an N-terminal 6×His tag, a DNA fragment (ahpC-G57) in which the Cys codon (TGC) at position 57 in ahpC was changed to a Gly codon (GGC) was synthesized (GenScript) and then cloned into pCR2.1-TOPO to generate pLS1000. pLS1001 was digested with BsmBI to release the DNA fragment containing ahpC-G57 which was then cloned into pBAD/HisA digested with Ncol/HindIII to produce pLS1001. Recombinant DNA techniques were conducted as previously described (50). Oligonucleotide primers were obtained from Integrated DNA Technologies. DNA sequencing was performed by AGCT, Inc.

**Hcp1 overexpression.** For purification of AhpC and AhpC<sup>CC57G</sup>, E. coli TOP10(pRR1000, pLS1001) cells were grown to mid-log phase in LB broth, and protein expression was induced using 0.02% L-arabinose (Sigma). Bacterial pellets were resuspended in B-PER (Pierce) plus Benzonase (Novagen) and lysozyme (100 μg/mL) and incubated for 20 min at room temperature with gentle agitation. Insoluble material was removed by centrifugation, and the resulting supernatant was loaded onto a gravity-fed Ni-nitrilotriacetic acid (NTA) agarose (Invitrogen) column. The column was washed with wash buffer (40 mM Tris [pH 8.0], 300 mM NaCl, and 40 mM imidazole), and protein was eluted with elution buffer (40 mM Tris [pH 8.0], 50 mM NaCl, and 300 mM imidazole) and then dialyzed against phosphate-buffered saline (PBS). The resulting protein was then loaded onto a gravity-fed His-Pur cobalt resin (Thermo Scientific) column, washed with imidazole-free wash buffer (40 mM Tris [pH 8.0], 300 mM NaCl), eluted with elution buffer, and dialyzed against PBS. The AhpC and AhpC<sup>CC57G</sup> preparations used in peroxidase activity assays were purified in the presence of 0.25 mM TCEP (Thermo Scientific) to maintain them in a reduced state prior to dialysis into PBS. Recombinant Hcp1 harboring an N-terminal 6×His tag was purified from *E. coli* TOP10(pBAD8mhpC1-6HisF), as previously described (37). Protein concentrations were determined using a BCA protein assay kit (Pierce). Endotoxin removal was performed using Pierce high-capacity endotoxin removal resin. The amount of endotoxin in the purified protein preparations was quantitated using a Pierce LAL chromogenic endotoxin quantitation kit as per the manufacturer’s instructions. Purified proteins were filter sterilized using a 0.45-μm-pore syringe filter and then stored at 4°C.

**SDS-PAGE.** Protein samples were mixed with an equal volume of 2× SDS-PAGE sample buffer and heated to 100°C for 10 min prior to electrophoresis on Bolt 12% Bis-Tris Plus gels (Invitrogen). Proteins were visualized using SimplyBlue SafeStain (Invitrogen).

**Peroxidase activity assay.** The enzymatic activities of AhpC and AhpC<sup>CC57G</sup> were determined indirectly by measuring the reduction of hydrogen peroxide using a quantitative peroxidase assay kit (Pierce). This assay measures hydrogen peroxide levels in biological samples using an iron and xylene orange reagent. In a 96-well plate (Costar), 170 ng H<sub>2</sub>O<sub>2</sub> was combined with 20 μg of purified AhpC or AhpC<sup>CC57G</sup> and incubated for 10 min. To quantify residual peroxide, the iron and xylene orange reagent was prepared per the manufacturer’s instructions and added to each of the wells. The plate was incubated for 30 min at room temperature and then read at 595 nm using a FLUOstar Omega microplate reader (BMG Labtech). HRP (Sigma) and Hcp1 were used as positive and negative controls, respectively. Two independent experiments were performed in duplicate. To determine the maximal amount of H<sub>2</sub>O<sub>2</sub> that could be reduced, the absorbance of 170 ng of H<sub>2</sub>O<sub>2</sub> was determined in the absence of protein. Using the total H<sub>2</sub>O<sub>2</sub> as a baseline, the amount of residual H<sub>2</sub>O<sub>2</sub> in samples was calculated based on a change in the absorbance from the baseline.

**Ethics statement.** All investigations involving animals were conducted in strict accordance with the recommendations in the *Guide for the Care and Use of Laboratory Animals* (51). Protocols were approved by the Animal Care and Use Committees at the University of Nevada, Reno (protocol no. 00785), or the University of Texas Medical Branch (protocol no. 0503014D) as well as by the U.S. Army Medical Research and Development Command Animal Care and Use Review Office (protocol no. CB 2018-07.01 and CB 2018-07.02). Mice were housed in microisolator cages under pathogen-free conditions, provided with rodent feed and water *ad libitum*, and maintained on a 12-h light cycle.

**Mouse immunizations.** For peptide mapping studies, 6- to 8-week-old female C57BL/6 mice (*n* = 12) (Charles River Laboratories) were immunized subcutaneously on days 0, 21, and 35 with AhpC<sup>CC57G</sup> (5 μg/dose) formulated in PBS (pH 7.2) (Gibco) with Alhydrogel at 2% (500 μg/dose) (Brenntag) and Cpg (20 μg/dose) (ODN 2006; InvivoGen) as the adjuvant system. One week after the final boost, spleens were harvested from terminally bled mice, and single-cell suspensions were prepared for use in ELISPOT assays as described below.

For T cell depletion studies, 6- to 8-week-old female C57BL/6 mice (*n* = 9) (Charles River Laboratories) were immunized subcutaneously on days 0, 21, and 35 with AhpC<sup>CC57G</sup> (5 μg/dose) formulated in PBS (pH 7.2) (Gibco) with Alhydrogel at 2% (500 μg/dose) (Brenntag) and Cpg (20 μg/dose) (ODN 2006; InvivoGen) as the adjuvant system. One week after the final boost, spleens were harvested from terminally bled mice, and single-cell suspensions were prepared for use in ELISPOT assays as described below.
adjacent system. One week after the final boost, spleens were harvested from terminally bled mice, and single-
cell suspensions were prepared for use in CD4+ and CD8+ T cell depletion experiments, as described below.

For the immunogenicity and challenge studies, 6- to 8-week-old female C57BL/6 mice (n = 16) (Charles River Laboratories) were immunized subcutaneously on days 0, 21, and 35 with CPS-CRM197 (2.5 μg/dose of CPS as a conjugate) plus AhpC<sup>STG</sup> (5 μg/dose) formulated in PBS (pH 7.2) (Gibco) with Alhydrogel at 2% (250 μg/dose) (Brenntag) and CpG (10 μg/dose) (ODN 2006; InvivoGen) as the adjuvant system. Mice (n = 16) immunized with adjuvant only served as the control group. One week after the final boost (day 42), serum and spleens were collected from terminally bled mice (n = 6 per group) and used in ELISpot assays, ELISAs, or opsonophagocytosis assays, as described below. The remaining mice in each group were used in challenge studies, as described below.

**AhpC peptide library.** The primary sequence of AhpC<sup>STG</sup> was used to design and synthesize a
ThinkPeptides PepScreen peptide library consisting of 35 peptides that were 15 amino acids in length and
overlapped by 10 amino acids (ProImmune) (Table 2). Peptides were resuspended in dimethyl sulfoxide (DMSO) at a concentration of 10 μg/mL or 20 μg/mL (based on solubility) and stored at −20°C until required for use in ELISpot assays.

**ELISpot assays.** Spleens were harvested from immunized mice, and single-cell suspensions were pre-
pared by passing the organs through 70-μm-pore cell strainers (Falcon) into RPMI 1640 (Gibco) medium supplemented with 10% (vol/vol) heat-inactivated (HI) fetal bovine serum (RPMI-10). Cells were pelleted by centrifugation (450 × g), resuspended in Sigma red blood cell lysis solution, incubated at room temperature for 10 min, pelleted (450 × g) again, and then resuspended in RPMI-10. Mouse IFN-γ, IL-5, and IL-17 ImmunoSpot ELISpot kits (Cellular Technology, Ltd.) were used per the manufacturer’s instructions. Splenocytes at a concentration of 2.5 × 10<sup>6</sup> cells/well were stimulated with AhpC<sup>STG</sup> (2 μg/well), AhpC peptides (4 μg/well), or RPMI-10, or RPMI-10 in an atmosphere of 5% CO<sub>2</sub>. The ELISpot plates were processed and developed per the manufacturer’s instructions. Plates were imaged using an ImmunoSpot S6 analyzer (Cellular Technology, Ltd.). IFN-γ, IL-5, and IL-17-secreting T cells were quanti-
tated using ImmunoSpot v7.0.22.0 Professional DC Smart Count software (Cellular Technology, Ltd.).

**CD4+ and CD8+ T cell depletion.** Spleens were harvested from immunized mice (n = 9), and single-
cell suspensions were prepared by passing the organs through 70-μm-pore cell strainers into RPMI-10. Cells were pelleted by centrifugation (450 × g), resuspended in red blood cell lysis solution (Sigma), and then incubated at room temperature for 10 min. Cells were washed twice by being pelleted (450 × g) and then resuspended in RPMI-10, and then they were passed through a 40-μm-pore cell strainer (Falcon). Prior to treatment for T cell depletion, splenocytes prepared from 3 individual spleens were pooled, resulting in 3 groups of splenocytes. Each group was then split into 3 equal aliquots and individ-
ually processed for (i) CD4+ T cell depletion or (ii) CD8+ T cell depletion or (iii) were not depleted. CD4+ or CD8+ T cells were depleted by positive selection using magnetic antibody cell separation (MACS) CD4 (L3T4) MicroBeads and CD8a (LY-2) MicroBeads with LD separation columns (Miltenyi) per the manufac-
turer’s instructions. The undepleted samples (not treated with MicroBeads) were run on MACS LD sepa-
ration columns for control purposes. The column eluates were pelleted by centrifugation (450 × g) and then resuspended in RPMI-10. Mouse IFN-γ-ELISpot assays were conducted as described above.

**Analysis of antibody titers.** Terminal bleeds were conducted on immunized mice (n = 6 per group) 1 week after the final boost. Serum was processed using Vacutainer SST tubes (BD) per the manufacturer’s instructions and stored at −80°C until required for use. Antibody responses directed against the vaccine anti-
gens were assessed by ELISA as previously described. Briefly, 96-well Maxisorp plates (Nunc) were coated overnight at 4°C with purified AhpC<sup>STG</sup> or CPS (1 μg/mL) solubilized in carbonate buffer (pH 9.6). The plates were blocked at room temperature for 30 min with StartingBlock T20 (Cellular Technology, Ltd.) and then incubated for 1 h at 37°C with mouse serum samples serially diluted in TBS plus 0.05% Tween 20 (TBST; pH 7.5) plus 1% StartingBlock T20. To facilitate detection, the plates were incubated for 1 h at 37°C with 1/2,000 dilutions of anti-mouse IgM, IgG, IgG1, IgG2b, or IgG2c HRP-conju-
gated antibodies (Southern Biotech). The plates were developed with TMB (3,3',5,5'-tetramethylbenzidine) substrate (KPL) and read at 620 nm using a FLUOstar Omega microplate reader (BMG Labtech). The reciprocals of the highest dilutions exhibiting optical densities (ODs) that were 3+ background levels were used to determine the endpoint titers for the individual mice.

**Western immunoblotting.** B. pseudomallei Bp82 and B. thailandensis E555 whole-cell lysates were separated on Bolt 12% Bis-Tris Plus gels and electrophoretically transferred to nitrocellulose membranes. The membranes were blocked with StartingBlock T20 (TBS) blocking buffer (Thermo Scientific) and then incubated for 1 h at 37°C with mouse serum samples serially diluted in TBS plus 0.05% Tween 20 (TBST; pH 7.5) plus 10% StartingBlock T20. To facilitate detection, the plates were incubated for 1 h at 37°C with 1/2,000 dilutions of anti-mouse IgM, IgG, IgG1, IgG2b, or IgG2c HRP-conju-
gated antibodies (Southern Biotech). The plates were developed with TMB (3,3',5,5'-tetramethylbenzidine) substrate (KPL) and read at 620 nm using a FLUOstar Omega microplate reader (BMG Labtech). The reciprocals of the highest dilutions exhibiting optical densities (ODs) that were 3+ background levels were used to determine the endpoint titers for the individual mice.

**Opsonophagocytosis assays.** Opsonophagocytosis assays were conducted essentially as previously
described (19). Briefly, B. thailandensis E555 cultures grown to early log phase were pelleted, resus-
pended at a density of 1 × 10<sup>8</sup> CFU/mL in Dulbecco’s modified Eagle’s medium (DMEM) or DMEM con-
taining 1% adjuvant only, AhpC<sup>STG</sup>, or CPS-CRM197 plus AhpC<sup>STG</sup> mouse immune serum (pooled and
heat inactivated for 30 min at 56°C) and incubated at 37°C for 1 h. The opsonized bacterial suspensions
were added to RAW 264.7 cells (1 × 10<sup>6</sup> cells/well) and incubated at 37°C in an atmosphere of 5% CO<sub>2</sub>
for 1 h. Infected monolayers were then washed twice with Hank’s balanced salt solution (HBSS)
(Gibco) and incubated with fresh DMEM-10 containing 250 μg/mL kanamycin for 2 h. Following this, the
infected monolayers were washed twice with HBSS and lysed with 0.2% (vol/vol) Triton X-100 (Sigma), and serial dilutions of the lysates were plated onto LB agar plates and incubated at 37°C for

---

AhpC as a Novel Melioidosis Vaccine Candidate Infection and Immunity August 2022 Volume 90 Issue 8 10.1128/iai.00222-22
approximately 48 h. Plate counts were used to enumerate bacterial loads. Three independent experiments were performed in duplicate.

Mouse challenge studies. Five weeks after the final boost (day 70), control and immunized mice (n = 10 per group) were challenged via an inhalational route with B. pseudomallei K96243, as previously described (19, 52). Briefly, groups of mice were exposed to aerosolized bacteria at nebulizer concentrations of \(4.48 \times 10^4\) to \(4.96 \times 10^7\) CFU/mL for 15 min at a constant flow rate of 30 L/min. Doses presented (Dp) to each group of animals were determined by performing standard CFU counts on the samples and then using the following formulas: (I) Dp (CFU) = \(C_{\text{crit}}\) (CFU/mL) \times exposure time (min) \times min vol (mL) and (II) min vol = 2.1wä8\(g^{3/2}\). In the adjuvant-only group, 5 mice received 20 LD\(_{50}\) (Dp = 2,940 CFU) and 5 mice received 29 LD\(_{50}\) (Dp = 4,340 CFU). In the conjugate-plus-AhpCC57G group, 5 mice received 27 LD\(_{50}\) (Dp = 4,040 CFU) and 5 mice received 28 LD\(_{50}\) (Dp = 4,180 CFU). Weight and survival of the challenged mice were monitored for 35 days. Humane endpoints were strictly observed via daily monitoring throughout the study.

Statistical analyses. All graphs were produced by using GraphPad Prism 8.2.0 (GraphPad Software, Inc.). Opossumaphagocytosis and ELISPot assay data were analyzed using a Mann-Whitney U test. Survival data were analyzed using a log-rank (Mantel-Cox) test.

ACKNOWLEDGMENTS

This research was supported by Defense Threat Reduction Agency contract HDTRA1-18-C-0062 and by startup funds from the University of Nevada, Reno.

Laura Meadows, Dana Reed, and Rosemary Roberts are acknowledged for technical assistance.

The authors are responsible for the contents of this article. We declare no conflict of interest.

REFERENCES

1. Burtnick MN, Heiss C, Roberts RA, Schweizer HP, Azadi P, Brett PJ. 2012. Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and gliandors. Front Cell Infect Microbiol 2:108. https://doi.org/10.3389/fcimb.2012.00108.

2. Yee KC, Lee MK, Chua CT, Puthucheary SD. 1988. Melioidosis, the great mimicker: a report of 10 cases from Malaysia. J Trop Med Hyg 91:249–254.

3. Currie BJ. 2015. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med 36:111–125. https://doi.org/10.1056/SSMCR.1304-139839.

4. Currie BJ, Ward L, Cheng AC. 2010. The epidemiology and clinical spectrum of melioidosis: 40 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 4:e900. https://doi.org/10.1371/journal.pntd.0000900.

5. Holden MT, Titball RW, Peacock SJ, Cerdeño-Tárraga AM, Atkins T, Crossman LC, Pitt T, Churcher C, Mungall K, Bentley SD, Sebaiha M, Thomson NR, Bason N, Beacham IR, Brooks K, Brown KA, Brown NF, Challis GL, Cherevach I, Chillingworth T, Cronin A, Crossett B, Davis P, DeShazer D, Feltwell T, Fraser A, Hance Z, Hauser H, Holroyd S, Jagels K, Keith KE, Maddison M, Moule S, Price C, Quail MA, Rabinowitsch E, Rutherford K, Sanders M, Simmonds M, Songsvilai S, Stevens K, Tumapa V, Vesaratchavest M, Whitehead S, Yeats C, Barrell BG, Oyston PC, Parkhill J. 2004. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A 101:14240–14245. https://doi.org/10.1073/pnas.0403302101.

7. Stone JK, DeShazer D, Brett PJ, Burtnick MN. 2014. Melioidosis: molecular aspects of pathogenesis. Expert Rev Anti Infect Ther 12:1487–1499. https://doi.org/10.1586/14787214.2014.970634.

8. Wiersinga WJ, Virk HS, Torres AG, Currie BJ, Peacock SJ, Dance DAB, Linnathamurtosakul D, Moyer CL, Rolim DB, Bertherat E, Day NP, Peacock SJ, Hay SI. 2016. Predicted spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. Clin Exp Immunol 196:178–188. https://doi.org/10.1111/cei.13286.
37. Pumpuang A, Dunachie SJ, Phokrai P, Jenjaroen K, Sintiprungrat K, Guimaraes BG, Souchon H, Honore N, Saint-Joanis B, Brosch R, Shepard N, Sunyakumthorn P, Hongsuwan M, Wuthiekanun V, Fletcher HA, Teparrukkul P, Limmathurotsakul D, Day NPJ, Dunachie SJ. 2015. T-cell responses are associated with survival in acute melioidosis patients. PLoS Negl Trop Dis 9:e0004152. https://doi.org/10.1371/journal.pntd.0004152.

38. Chaichana P, Jenjaroen K, Chumsong S, Sounimwiyong M, Rongkrd P, Kotronenste B, Teparrukkul P, Limmathurotsakul D, Day NPJ, Channatrasit N, Dunachie SJ. 2019. Role of Burkholderia pseudomallei-specific IgG2 in adults with acute melioidosis, Thailand. Emerg Infect Dis 27:463–470. https://doi.org/10.3202/eid2702.200213.

39. Kovacs-Simon A, Hemsley CM, Scott AE, Prior JL, Titball RW. 2019. Burkholderia thailandensis strain EI55 is a surrogate for the investigation of Burkholderia pseudomallei replication and survival in macrophages. BMC Microbiol 19:97. https://doi.org/10.1186/s12866-019-1469-9.

40. Jenjaroen K, Chumsong S, Sounimwiyong M, Ariyaprasert P, Channatrasit N, Sunyakumthorn P, Hongsuwan M, Wuthiekanun V, Fletcher HA, Teparrukkul P, Limmathurotsakul D, Day NPJ, Dunachie SJ. 2015. T-cell responses are associated with survival in acute melioidosis patients. PLoS Negl Trop Dis 9:e0004152. https://doi.org/10.1371/journal.pntd.0004152.

41. O’Riordan AA, Morales VA, Mulligan L, Faheem N, Windle HJ, Kelleher DP. 2012. Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. Vaccine 30:378–388. https://doi.org/10.1016/j.vaccine.2012.04.002.

42. Erb JK, Kimman J, Woodfield L, Wilson T, Collins DM, Watson JD, LeGros G. 1998. Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from Mycobacterium tuberculosis. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice. Vaccine 16:692–697. https://doi.org/10.1016/S0264-410X(97)00253-3.

43. Lou H, Li X, Guo F, Ding M, Hu Y, Chen H, Yan J. 2019. Evaluations of alkyl hydroperoxide reductase B cell antigen epitope as a potential epitope vaccine against Campylobacter jejuni. Saudi J Biol Sci 26:1117–1122. https://doi.org/10.1016/j.sjbs.2019.05.011.

44. Guo SH, Wang HF, Nian ZG, Wang YD, Zeng QY, Zhang G. 2017. Immunization with alkyl hydroperoxide reductase subunit C reduces Burkholderia pseudomallei – immunoreactive protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A 104:13499–13504. https://doi.org/10.1073/pnas.0702810104.

45. Erb KJ, Kirman J, Woodfield L, Wilson T, Collins DM, Watson JD, LeGros G. 1998. Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from Mycobacterium tuberculosis. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice. Vaccine 16:692–697. https://doi.org/10.1016/S0264-410X(97)00253-3.

46. Lou H, Li X, Guo F, Ding M, Hu Y, Chen H, Yan J. 2019. Evaluations of alkyl hydroperoxide reductase B cell antigen epitope as a potential epitope vaccine against Campylobacter jejuni. Saudi J Biol Sci 26:1117–1122. https://doi.org/10.1016/j.sjbs.2019.05.011.

47. Guo SH, Wang HF, Nian ZG, Wang YD, Zeng QY, Zhang G. 2017. Immunization with alkyl hydroperoxide reductase subunit C reduces Burkholderia pseudomallei – immunoreactive protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A 104:13499–13504. https://doi.org/10.1073/pnas.0702810104.

48. Ryu K, Lim CA, Eddjerdjian-Bromage H, Tempst P, Nathan C. 2002. Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein. Science 295:1073–1076. https://doi.org/10.1067/j.vimb.1998.120742.

49. Erb KJ, Kirman J, Woodfield L, Wilson T, Collins DM, Watson JD, LeGros G. 1998. Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from Mycobacterium tuberculosis. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice. Vaccine 16:692–697. https://doi.org/10.1016/S0264-410X(97)00253-3.

50. Lou H, Li X, Guo F, Ding M, Hu Y, Chen H, Yan J. 2019. Evaluations of alkyl hydroperoxide reductase B cell antigen epitope as a potential epitope vaccine against Campylobacter jejuni. Saudi J Biol Sci 26:1117–1122. https://doi.org/10.1016/j.sjbs.2019.05.011.

51. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.

52. Massey S, Yeager LA, Blumentritt CA, Vijayakumar S, Sbrana E, Peterson BW, Bracken S, Chung J, Sakowski C, Kim Y. 2010. Identification of novel immunoreactive proteins of Staphylococcus zoosporogenicus with potential as vaccine components. Vaccine 31:4129–4135. https://doi.org/10.1016/j.vaccine.2012.04.002.

53. Perry MB, MacLean LL, Schollaardt T, Bryan LE, Ho M. 1995. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect Immun 63:3348–3352. https://doi.org/10.1128/IAI.63.9.3348-3352.1995.

54. Burtnick MN, Brett PJ. 2013. Burkholderia mallei and Burkholderia pseudomallei cluster 1 type VI secretion system gene expression is negatively regulated by iron and zinc. PLoS One 8:e76767. https://doi.org/10.1371/journal.pone.0076767.

55. Sim BM, Chantrarat N, Ooi WF, Nandi T, Tewhey R, Wuthiekanun V, Thaipradungpan J, Tumapa S, Ariyaratne P, Sung WK, Sem XH, Chua HH, Wuthiekanun V, Fletcher HA, Teparrukkul P, Limmathurotsakul D, Day NPJ, Dunachie SJ. 2015. T-cell responses are associated with survival in acute melioidosis patients. PLoS Negl Trop Dis 9:e0004152. https://doi.org/10.1371/journal.pntd.0004152.

56. Probst KL, Mima T, Choi KH, Dow SW, Schweizer HP. 2010. A Burkholderia pseudomallei deltaperM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists. Infect Immun 78:3136–3143. https://doi.org/10.1128/IAI.01313-09.

57. Sim BM, Chantrarat N, Ooi WF, Nandi T, Tewhey R, Wuthiekanun V, Thaipradungpan J, Tumapa S, Ariyaratne P, Sung WK, Sem XH, Chua HH, Ramnarayan K, Lin CH, Liu Y, Fei EJ, Glass MB, Tan G, Peacock SJ, Tan P. 2010. Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolates. Genome Biol 11:849. https://doi.org/10.1186/gb-2010-11-8-849.

AhpC as a Novel Melioidosis Vaccine Candidate

Infection and Immunity

August 2022 Volume 90 Issue 8 10.1128/aii.00222-22